DrugPatentWatch Database Preview
Patent: 10,035,817
Summary for Patent: 10,035,817
| Title: | Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane |
| Abstract: | The invention provides processes for preparing purified cell-binding agent cytotoxic agent conjugates comprising subjecting a mixture comprising a cell-binding agent cytotoxic agent conjugate and one or more impurities to a polyvinyl difluoride (PVDF) membrane to remove at least a portion of the impurities from the mixture, thereby providing a purified cell-binding agent cytotoxic agent conjugate. |
| Inventor(s): | Chen; Xiaoxi Kevin (Natick, MA), Li; Xinfang (Newton, MA) |
| Assignee: | IMMUNOGEN, INC. (Waltham, MA) |
| Application Number: | 14/430,701 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,035,817
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | ⤷ Try it Free | IMMUNOGEN, INC. (Waltham, MA) | 2032-10-04 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | ⤷ Try it Free | IMMUNOGEN, INC. (Waltham, MA) | 2032-10-04 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | ⤷ Try it Free | IMMUNOGEN, INC. (Waltham, MA) | 2032-10-04 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | ⤷ Try it Free | IMMUNOGEN, INC. (Waltham, MA) | 2032-10-04 | RX | Orphan | search |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | ⤷ Try it Free | IMMUNOGEN, INC. (Waltham, MA) | 2032-10-04 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | ⤷ Try it Free | IMMUNOGEN, INC. (Waltham, MA) | 2032-10-04 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,035,817
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201502992 | ⤷ Try it Free |
| World Intellectual Property Organization (WIPO) | 2014055877 | ⤷ Try it Free |
| United States of America | 2015225446 | ⤷ Try it Free |
| United States of America | 2019031712 | ⤷ Try it Free |
| Singapore | 10201702737T | ⤷ Try it Free |
| Singapore | 11201502429Y | ⤷ Try it Free |
| Russian Federation | 2015116882 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
